경량석재 커튼월 개발을 위한 기초물성의 실험적 연구(1)

서동훈,김우재,박선길,김영희,정상진 대한건축학회 2000 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.20 No.1

사이버 니르바나 2092

서동훈 나비클럽 2024 계간 미스터리 Vol.- No.81

문화콘텐츠 창작을 위한 창의적 문화교육 방안 연구

서동훈,김효정 한국청소년정책연구원 2005 한국청소년정책연구원 연구보고서 Vol.- No.-

동양정신과 소설

서동훈 문예운동사 1982 문예운동 Vol.- No.33

1D-CNN 기반 LIB 상태 진단 시스템 개발

서동훈,신종호 제어·로봇·시스템학회 2023 제어·로봇·시스템학회 논문지 Vol.29 No.5

LIB (Lithium Ion Battery) has been widely utilized in various fields due to its high energy density and long usage cycle, and is particularly actively applied as a power source for unmanned vehicles. LIBs deteriorate with repeated charge/discharge cycles, reducing usable capacity, and the LIB's power performance is determined by the available capacity. Therefore, in order to smoothly supply power to unmanned vehicles, LIBs with guaranteed available capacity must be used. In this paper, we propose a learning-based LIB status diagnosis system to effectively determine the available capacity of LIB. The proposed system is constructed using a convolutional neural network-based classification model, extracts and synthesizes features from diagnostic data, and outputs LIB status diagnosis results. The state of the LIB is defined as three states depending on the operating conditions of the vehicle and the available capacity of the LIB, and diagnostic data is generated based on the time-series discharge data to effectively reflect the deterioration characteristics of the LIB. To verify the performance of the proposed state diagnosis system, model training and verification are conducted using random discharge data and confusion matrix, and the results are analyzed.

Major clinical research advances in gynecologic cancer in 2010

서동훈,김재원,김기동,강순범 대한부인종양학회 2010 Journal of Gynecologic Oncology Vol.21 No.4

This review summarizes 11 major clinical research advances in gynecologic oncology in 2010. For ovarian cancer,bevacizumab as a leading molecular targeted agent, pegylated liposomal doxorubicin in recurrent disease, the role of neoadjuvant chemotherapy in an advanced setting, an effective screening method, and ARID1A mutations as a clue to the origin of clear cell carcinoma are mentioned. For cervical cancer, confirmation of the efficacy and the introduction of a self collection method of the human papillomavirus (HPV) test, and the association between the HPV vaccine and miscarriage are examined. For endometrial cancer, the superiority of laparoscopy in staging operation, the role of vaginal brachytherapy in an adjuvant setting, and the effect of para-aortic lymph node dissection are reviewed. In addition, the trend of geriatric oncology and chemotherapy in carcinosarcomas is also assessed.

쇄골밑정맥 카테터삽입 시 천자 횟수를 증가시키는 요인

서동훈,강희철,윤방부,오동희,서희선,조경희,김경곤 대한가정의학회 2006 Korean Journal of Family Medicine Vol.27 No.4

연구배경: 중심 정맥 카테터삽입은 중심 정맥압의 측정, 수액과 혈액의 빠른 주입, 고단위 영양수액의 투여뿐만 아니라 패혈증상, 심장성 및 혈액량 감소 쇼크의 치료, 혈관 작용성 약제의 투여 등에 널리 이용되어 왔다. 중심 정맥 카테터삽입 시 흔히 발생하는 기계적 합병증은 동맥천자, 혈종, 기흉, 혈흉이 있으며, 이러한 합병증을 줄일 수 있는 관련 요소들을 알아내고자 본 연구를 시행하였다. 방법: 2003년 9월 1일부터 11월 30일까지 일산병원에서 쇄골밑정맥 카테터삽입을 시술한 가정의학과 전공의를 대상으로 시술 직후 시행한 설문을 통해 40예의 쇄골밑정맥 카테터삽입에 대한 정보를 수집하여 1, 2회만 시도한 경우와 3회 이상 시도한 경우, 각각 두 군으로 분류하여 연관된 요인을 분석하였다. 결과: 천자 횟수가 3회 미만인 경우가 23건이었고, 3회 이상인 경우가 17건이었다. 천자 횟수가 3회 미만인 경우와 3회 이상인 군을 비교했을 때 통계학적으로 유의한 차이를 보였던 요소는 환자의 혈색소 수치, 환자의 해부학적 이상 유무, 과거 술기 경험 횟수(20회), 시술 전 천자부위 표시하기(puncture site marking), 삽입위치(쇄골 정중앙선)이다. (P<0.05). 결론: 쇄골밑정맥 삽관 시 합병증을 줄이기 위해선 천자 횟수를 3회 미만으로 줄이는 것이 바람직한데, 이에 영향을 미치는 시술자 요소는 풍부한 술기 경험과 시술 전 천자부위 표시하기, 쇄골정중앙선에서의 삽입이다. Factors Attributing to Increasing Attempts at Central Venous CatheterizationDong Hoon Suh, M.D., Dong Hee Oh, M.D., Hee Sun Seo, M.D.*, Kyung Hee Cho, M.D., Ph.D.*, Kyoung Kon Kim, M.D.†, Hee Cheol Kang, M.D., Ph.D., Bang Bu Youn, M.D., Ph.D.

Laparoscopic surgery is a current tide of widely accepted standard procedure for endometrial cancer

서동훈,김재원 대한부인종양학회 2010 Journal of Gynecologic Oncology Vol.21 No.2

Major clinical research advances in gynecologic cancer in 2013

서동훈,김재원,강석범,김학재,이경훈 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.3

In 2013, 10 topics were selected for major clinical research advances in gynecologic oncology; these included three topics regarding cervical cancer, three regarding ovarian cancer, two regarding endometrial cancer, and one each regarding breast cancer and radiation oncology. For cervical cancer, bevacizumab was first demonstrated to exhibit outstanding clinical efficacy in a recurrent, metastatic setting. Regarding cervical cancer screening, visual inspections with acetic acid in low-resource settings, p16/Ki-67 double staining, and the follow-up results of four randomized controlled trials of human papillomavirus-based screening methods were reviewed. Laparoscopic para-aortic lymphadenectomy before chemoradiation for locally advanced cervical cancer was the final topic for cervical cancer. Regarding front-line ovarian cancer therapies, dose-dense paclitaxel and carboplatin, intraperitoneal chemotherapy, and other targeted agents administered according to combination or maintenance schedules were discussed. Regarding recurrent ovarian cancer treatment, cediranib, olaparib, and farletuzumab were discussed for platinum-sensitive disease. The final overall survival data associated with a combination of bevacizumab and chemotherapy for platinum-resistant disease were briefly summarized. For endometrial cancer, the potential clinical efficacy of metformin, an antidiabetic drug, in obese patients was followed by integrated genomic analyses from the Cancer Genome Atlas Research Network. For breast cancer, three remarkable advances were reviewed: the long-term effects of continued adjuvant tamoxifen for 10 years, the effects of 2-year versus 1-year adjuvant trastuzumab for human epidermal growth factor receptor 2-positive disease, and the approval of pertuzumab in a neoadjuvant setting with a pathologic complete response as the surrogate endpoint. Finally, the recent large studies of intensity-modulated radiotherapy for gynecologic cancer were briefly summarized.

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture

서동훈,김태훈,김재원,김선영,김희승,이택상,정현훈,김용범,박노현,송용상 대한부인종양학회 2013 Journal of Gynecologic Oncology Vol.24 No.4

Objective: To evaluate the improvement in prognosis prediction with reassignment of International Federation of Gynecology and Obstetrics (FIGO) stages for ovarian carcinoma. Methods: This was a retrospective study of patients with epithelial ovarian, fallopian tube, and primary peritoneal cancers. Sub-staging criteria used in stage reassignment were defined as follows: surgical spillage (IC1), capsule rupture before surgery or tumor on the surface (IC2), and positive cytology results (IC3); microscopic (IIB1) and macroscopic (IIB2) pelvic spread; microscopic extrapelvic spread (IIIA1) and retroperitoneal lymph node (LN) metastasis without extrapelvic spread (IIIA2); and supraclavicular LN metastasis (IVA) and other distant metastasis (IVB). Survival outcomes associated with the current and reassigned stages were compared. Results: Overall, 870 patients were eligible for analysis. The median follow-up period was 45 months (range, 0 to 263 months). The 5-year overall survival rates (5YSRs) according to the current staging were 93.5% (IA), 82.5% (IC), 75.0% (IIB), 74.5% (IIC), 57.5% (IIIA), 54.0% (IIIB), 38.5% (IIIC), and 33.0% (IV). The 5YSRs of patients with IC1, IC2, and IC3 after sub-staging were 92.0%, 85.0%, and 71.0%, respectively (p=0.004). Patients who were reassigned to stage IIIA2 had a better 5YSR than those with extrapelvic tumors >2 cm (66.3% vs. 35.8%; p=0.005). Additionally, patients with newly assigned stage IVA disease had a significantly better 5YSR than those with stage IVB disease (52.0% vs. 28.0%; p=0.015). Conclusion: The modified FIGO staging for ovarian carcinoma appears superior to the current staging for discriminating survival outcomes of patients with surgical spillage, retroperitoneal LN metastasis without extrapelvic peritoneal involvement, or distant metastasis to supraclavicular LNs.